NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that two oral presentations featuring gadofosveset trisodium, the first and only FDA approved blood pool contrast agent for magnetic resonance angiography (MRA), were presented at MRA-Club 09: The 21st Annual International Conference on Magnetic Resonance Angiography. The company also announced today that ABLAVAR™ has been chosen as the brand name for gadofosveset trisodium.
